| DIRECT COMPETITOR COMPARISON | |
| AEZS | CELG | ENMD | Pvt1 | Industry | | Market Cap: | 66.87M | 25.98B | 72.86M | N/A | 96.11M | | Employees: | N/A | 2,441 | 21 | N/A | 65 | | Qtrly Rev Growth (yoy): | -22.30% | 17.30% | 4.80% | N/A | 19.70% | | Revenue (ttm): | 30.30M | 2.56B | 7.64M | N/A | 14.01M | | Gross Margin (ttm): | 41.72% | 91.04% | 100.00% | N/A | 65.68% | | EBITDA (ttm): | -37.94M | 573.33M | -5.37M | N/A | -12.30M | | Oper Margins (ttm): | -150.75% | 16.83% | -72.16% | N/A | -137.11% | | Net Income (ttm): | -51.25M | 373.27M | -10.04M | N/A | N/A | | EPS (ttm): | -0.938 | 0.802 | -0.114 | N/A | -0.32 | | P/E (ttm): | N/A | 70.49 | N/A | N/A | 16.45 | | PEG (5 yr expected): | N/A | 1.17 | N/A | N/A | 1.28 | | P/S (ttm): | 2.21 | 10.16 | 9.53 | N/A | 9.57 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.55 | 0.00% | 57.24B | 12.33 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.38 | 0.00% | 13.70B | 15.86 | | Genzyme Corp. | GENZ | 50.27 | 0.00% | 13.34B | 28.66 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.26 | 0.00% | 41.63B | 17.89 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.25 | 0.00% | 8.96B | 1025.51 | | Teva Pharmaceutical Industries Limited | TEVA | 53.57 | 0.00% | 47.20B | 49.01 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.29 | 0.00% | 3.96B | 19.22 | | King Pharmaceuticals Inc. | KG | 11.67 | 0.00% | 2.90B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.20 | 0.00% | 5.56B | 111.66 | | Pfizer Inc. | PFE | 18.64 | 0.00% | 150.42B | 15.48 | | Johnson & Johnson | JNJ | 64.16 | 0.00% | 177.02B | 14.01 | | GlaxoSmithKline plc | GSK | 42.44 | 0.00% | 107.59B | 13.35 | | Sanofi-Aventis | SNY | 39.52 | 0.00% | 103.19B | N/A | | Novartis AG | NVS | 55.78 | 0.00% | 126.69B | 16.70 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.85 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.62 | 0.00% | 66.15B | 9.16 | | Abbott Laboratories | ABT | 54.24 | 0.00% | 83.90B | 14.70 | | Bristol-Myers Squibb Co. | BMY | 25.16 | 0.00% | 49.84B | 13.02 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | CELG | | Coverage initiated on Celgene by Soleil
Thu 7:22am -
Briefing.com | | • | CELG | | PREVIEW-Eyes on Celgene's Revlimid data at ASH meeting
Tue, Dec 1 -
at Reuters | | • | CELG | | Former J&J Executive Charged With Bribery
Tue, Dec 1 -
at TheStreet.com | | • | CELG | | Celgene: New Studies Expected to Boost Sales
Mon, Nov 30 -
at Seeking Alpha | | • | CELG | | Johnson & Johnson: Good & Bad News
Mon, Nov 30 -
at TheStreet.com | | • | CELG | | 13 Biotechs to Watch for at Hematology Conference
Mon, Nov 30 -
at Seeking Alpha | | • | CELG | | Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program
Fri, Nov 27 -
Business Wire | | • | ENMD | | ENTREMED INC Financials
Fri, Nov 20 -
EDGAR Online Financials | | • | ENMD | | ExpressJet, Entremed: Midday Volume Plays
Mon, Nov 16 -
at TheStreet.com | | • | ENMD | | EntreMed reports 3Q profit on lower costs
Mon, Nov 16 -
AP | | • | ENMD | | EntreMed ekes out profit
Mon, Nov 16 -
at bizjournals.com | | • | ENMD | | ENTREMED INC Files SEC form 8-K, Results of Operations and Financial Condition
Mon, Nov 16 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.83% Nasdaq 0.00%
Competitors
